ONCY vs ORKA

Oncolytics Biotech Inc. vs Oruka Therapeutics, Inc. — Valuation Comparison 2026

ONCY

Biotechnology
Oncolytics Biotech Inc.
Quality
3.4
out of 10
Value Trap
Price
$0.94
Last close
Models
7/13
Active
VS

ORKA

Biotechnology
Oruka Therapeutics, Inc.
Quality
4.3
out of 10
Value Trap
12
SAFE
Price
$57.98
Last close
Models
10/13
Active

Model-by-Model Comparison

ModelType ONCY Fair ValueONCY Upside ORKA Fair ValueORKA Upside
Bayesian DCF Intrinsic $0.27 -70.9% $17.90 -69.1%
Earnings Power Value Intrinsic $31.09 -55.0%
EROIC Spread Intrinsic $•••.•• ••.•% $•••.•• ••.•%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
Markov DDM Intrinsic $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $•••.•• ••.•% $•••.•• ••.•%
Dynamic NAV Asset-Based $0.16 -82.7% $5.63 -90.3%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for ONCY vs ORKA — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

ONCY vs ORKA — Which Stock Is More Undervalued?

ORKA scores higher with a 4.3/10 quality rating vs ONCY's 3.4/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Oncolytics Biotech Inc. (ONCY) and Oruka Therapeutics, Inc. (ORKA) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

ONCY currently trades at $0.94 with a QOC of 3.4/10, while ORKA trades at $57.98 with a QOC of 4.3/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).